TD 139
≥95%
- Product Code: 70856
CAS:
1450824-22-2
| Molecular Weight: | 648.64 g./mol | Molecular Formula: | C₂₈H₃₀F₂N₆O₈S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD29919388 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, dry sealed |
Product Description:
TD 139 is primarily investigated for its potential therapeutic applications in treating fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). It functions as a galectin-3 inhibitor, targeting the protein involved in the progression of fibrosis. By blocking galectin-3, TD 139 aims to reduce inflammation and fibrosis in affected tissues, offering a promising approach to slow or halt disease progression. Clinical trials are ongoing to evaluate its efficacy and safety in patients with IPF, with the hope of providing a novel treatment option for this challenging condition. Additionally, its mechanism of action suggests potential applications in other fibrotic disorders, such as liver and kidney fibrosis, expanding its therapeutic scope.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | white solid |
| PURITY | 94.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿8,120.00 |
+
-
|
| 0.005 | 10-20 days | ฿19,980.00 |
+
-
|
| 0.010 | 10-20 days | ฿36,800.00 |
+
-
|
TD 139
TD 139 is primarily investigated for its potential therapeutic applications in treating fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). It functions as a galectin-3 inhibitor, targeting the protein involved in the progression of fibrosis. By blocking galectin-3, TD 139 aims to reduce inflammation and fibrosis in affected tissues, offering a promising approach to slow or halt disease progression. Clinical trials are ongoing to evaluate its efficacy and safety in patients with IPF, with the hope of providing a novel treatment option for this challenging condition. Additionally, its mechanism of action suggests potential applications in other fibrotic disorders, such as liver and kidney fibrosis, expanding its therapeutic scope.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :